Foistar®(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra®(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients

Jae-Phil Choi, Hyoung-Jun Kim, Jumi Han, SuJung Park, JinJoo Han
doi: https://doi.org/10.1101/2020.12.10.20240689

Article usage

Article usage: December 2020 to November 2024

AbstractFullPdf
Dec 202031611114354
Jan 2021601137156
Feb 202131634137
Mar 202124922148
Apr 2021228383
May 2021152364
Jun 2021107440
Jul 202185348
Aug 202186840
Sep 202163151
Oct 202162146
Nov 202150147
Dec 202144120
Jan 202236420
Feb 202247117
Mar 20223405
Apr 202256214
May 202236413
Jun 202227189
Jul 20223749
Aug 202237718
Sep 202250414
Oct 202241210
Nov 202228110
Dec 20222859
Jan 20232349
Feb 20231578
Mar 20232517
Apr 202330911
May 202314110
Jun 202319511
Jul 20231665
Aug 2023281521
Sep 20233264
Oct 202320213
Nov 20231815
Dec 20233425
Jan 20241313
Feb 202424111
Mar 20241735
Apr 20241589
May 202414104
Jun 20242076
Jul 20241325
Aug 202426311
Sep 20241515
Oct 2024281010
Nov 20241147
Back to top
Posted December 15, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Foistar®(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra®(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients
Jae-Phil Choi, Hyoung-Jun Kim, Jumi Han, SuJung Park, JinJoo Han
medRxiv 2020.12.10.20240689; doi: https://doi.org/10.1101/2020.12.10.20240689
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area